Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.54 |
| ▸ | CA4 | P22748 | 1/20 | 0.54 |
| ▸ | CA6 | P23280 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | GSK3B | P49841 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845700 | 1.00 | PTPN1 (0.57) | PTPN1KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL9409754 | 0.85 | PTPN1 (0.65) | PTPN1KDM4EHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL16755709 | 0.83 | CYP19A1 (0.58) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL105808 | 0.81 | KDM4E (0.58) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL31211720 | 0.81 | CYP19A1 (0.66) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL598345 | 0.81 | MEN1 (0.69) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL6241330 | 0.79 | CYP19A1 (0.54) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL7826271 | 0.79 | KDM4E (0.56) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL9116330 | 0.78 | CYP19A1 (0.53) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 | |
| SCHEMBL6129338 | 0.77 | KDM4E (0.54) | KDM4EHPGDALDH1A1SMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9870909-B2 | Compositions and methods for mass spectometry | MSTM, LLC | 2018-01-16 | — | — | US | claimed |
| WO-2013052803-A2 | METHODS AND COMPOSITIONS COMPRISING A NITRITE-REDUCTASE PROMOTER FOR TREATMENT OF MEDICAL DISORDERS AND PRESERVATION OF BLOOD PRODUCTS | RADIORX, INC. (US) | 2013-04-11 | — | — | WO | claimed |
| EP-2094292-A2 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | Ikor, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| WO-2008051689-A2 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | IKOR, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| CN-101168565-A | Nitric oxide-blocked cross-linked tetrameric hemoglobin | IKOR INC (US) | 2008-04-30 | — | — | CN | claimed |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | GENENTECH, INC. | 2025-02-27 | — | — | US | disclosed |
| CN-115246826-B | Quaternary ammonium salt isoxazoline compound, its preparation and application as insecticidal and bactericidal agent | 瑞普（天津）生物药业有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-117820192-A | Gamma-lactam ring compound and preparation method and application thereof | 重庆理工大学 | 2024-04-05 | — | — | CN | disclosed |
| EP-3983420-B1 | 3,5-BIS(PHENYL)-1H-HETEROARYL DERIVATIVES AS MEDICAMENTS | INST OF BIOTECHNOLOGY CAS V V I (CZ) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023096987-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2023-06-01 | — | — | WO | disclosed |
| EP-0205069-A2 | 2,2-Diaryl-chromenothiazoles, their preparation and their use as recording materials | BAYER AG (DE) | 1986-12-17 | — | — | EP | disclosed |
| US-4588738-A | N-imidazolyl derivatives of 1,2,3,4-tetrahydro-naphthalene and indan as platelet aggregation inhibitors | FARMITALIA CARLO ERBA S.P.A. (IT) | 1986-05-13 | — | — | US | disclosed |
| US-4492707-A | ANTILIPEMIC AGENT | FARMITALIA CARLO ERBA S.P.A. (IT) | 1985-01-08 | — | — | US | disclosed |
| US-4364949-A | BACTERICIDE, FUNGICIDE | CIBA-GEIGY CORPORATION (US) | 1982-12-21 | — | — | US | disclosed |
| US-4342775-A | FOR USE AS ANTICOAGULANT AND REDUCING SERUM SHOLESTEROL OR SERUM TRIGLYCERIDES | FARMITALIA CARLO ERBA S.P.A. (IT) | 1982-08-03 | — | — | US | disclosed |
| EP-0031795-A1 | Hydroxyphenyl ketones | CIBA-GEIGY AG (CH) | 1981-07-08 | — | — | EP | disclosed |
| US-4190606-A | OF AN ALPHA-HALOGENATED CARBONYL COMPOUND BY-PRODUCT OF AN ALKENE OXIDATION USING A HYDROHALIC ACID | CELANESE CORPORATION (US) | 1980-02-26 | — | — | US | disclosed |
| US-4008279-A | OR PREVENTION OF HALOGENATIONOXIDATION CATALYST | CELANESE CORPORATION (US) | 1977-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250064945-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ADRM1, BRAP, VHL | PTPN1 3848/4885KDM4E 2143/4885HPGD 4163/4885 |
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | PTPN1 4150/4885KDM4E 3880/4885HPGD 3054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.